Mortality trends in multiple myeloma after the introduction of novel therapies in the United States-Reference-Cited by-同舟云学术

Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

Published:2021-10-26 Issue: Volume: Page:
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Binder Moritz^ORCID,Nandakumar Bharat,Rajkumar S. Vincent,Kapoor Prashant^ORCID,Buadi Francis K.^ORCID,Dingli David^ORCID,Lacy Martha Q.,Gertz Morie A.,Hayman Suzanne R.,Leung Nelson^ORCID,Fonder Amie,Hobbs Miriam,Hwa Yi Lisa,Muchtar Eli^ORCID,Warsame Rahma,Kourelis Taxiarchis V.^ORCID,Gonsalves Wilson I.,Russell Stephen,Lin Yi^ORCID,Siddiqui Mustaqeem,Kyle Robert A.,Dispenzieri Angela^ORCID,Kumar Shaji K.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01453-5.pdf

Reference30 articles.

1. Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016;43:682–9.

2. Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519–27.

3. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

4. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.

5. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–31.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview;International Journal of Molecular Sciences;2024-08-23

2. Treatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel;Journal of Hematology & Oncology;2024-06-06

4. Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities;Blood Cancer Journal;2024-05-28

5. Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes;Nature Communications;2024-05-16